Kangzhong Medical, a prominent player in China’s medical imaging sector listed on the Shanghai STAR Market, has announced a bold and potentially risky strategic shift. The company plans to acquire a controlling stake in Maide Intelligent Technology, an AI-focused healthcare startup, at a valuation of 750 million RMB. This move marks a significant escalation from a minority investment plan announced just two months ago, signaling an urgent desire to integrate artificial intelligence into its core hardware offerings.
The acquisition comes at a challenging time for the suitor. Kangzhong Medical recently reported a net loss for the 2025 fiscal year, citing intensified industry competition and rigid cost structures that have eroded its profit margins. By absorbing Maide Intelligent, which specializes in ultrasound AI diagnostic systems and genomic analysis platforms, Kangzhong hopes to find a "second growth curve" that can offset the volatility of its primary X-ray detector business.
However, the financial optics of the deal are raising eyebrows among market observers. Maide Intelligent is itself deeply in the red, recording substantial losses over the past two years as it struggles to transition from a project-based delivery model to a scalable, service-based operation. To hedge against this risk, the acquisition includes a rigorous performance commitment requiring Maide to reach 100 million RMB in revenue and achieve profitability by 2027.
Perhaps the most significant risk lies in the massive 370 million RMB in goodwill that will be added to Kangzhong’s balance sheet upon completion of the deal. This figure represents approximately 44% of the company's net assets, leaving little room for error. If the integration of "hardware plus software" fails to monetize as expected, the resulting goodwill impairment could pose a severe threat to the company’s future financial stability.